Envista Holdings Co. (NYSE:NVST) Receives Average Recommendation of “Hold” from Brokerages

Shares of Envista Holdings Co. (NYSE:NVST) have received an average rating of “Hold” from the fifteen brokerages that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $20.18.

NVST has been the subject of a number of recent analyst reports. New Street Research set a $19.00 price objective on Envista in a research report on Thursday, March 6th. JPMorgan Chase & Co. lowered their price objective on Envista from $20.00 to $19.00 and set a “neutral” rating for the company in a research report on Thursday, March 6th. Wells Fargo & Company set a $19.00 price objective on Envista in a research report on Saturday, March 8th. Mizuho initiated coverage on Envista in a research report on Wednesday, December 4th. They issued an “underperform” rating and a $20.00 price objective for the company. Finally, Morgan Stanley lowered their price objective on Envista from $20.00 to $19.00 and set an “equal weight” rating for the company in a research report on Thursday, March 6th.

Institutional Investors Weigh In On Envista

Several institutional investors and hedge funds have recently modified their holdings of the stock. Ariel Investments LLC lifted its stake in shares of Envista by 6.2% in the fourth quarter. Ariel Investments LLC now owns 12,059,624 shares of the company’s stock worth $232,630,000 after acquiring an additional 699,625 shares in the last quarter. Nuance Investments LLC lifted its stake in shares of Envista by 4.4% in the third quarter. Nuance Investments LLC now owns 7,346,534 shares of the company’s stock worth $145,168,000 after acquiring an additional 308,221 shares in the last quarter. Franklin Resources Inc. lifted its stake in shares of Envista by 72.6% in the fourth quarter. Franklin Resources Inc. now owns 6,854,506 shares of the company’s stock worth $132,223,000 after acquiring an additional 2,882,844 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Envista by 19.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 6,762,091 shares of the company’s stock worth $130,440,000 after acquiring an additional 1,089,923 shares in the last quarter. Finally, Gates Capital Management Inc. lifted its stake in shares of Envista by 15.1% in the fourth quarter. Gates Capital Management Inc. now owns 4,694,148 shares of the company’s stock worth $90,550,000 after acquiring an additional 615,577 shares in the last quarter.

Envista Stock Performance

NYSE NVST opened at $17.02 on Friday. Envista has a fifty-two week low of $15.15 and a fifty-two week high of $23.00. The stock has a market cap of $2.93 billion, a price-to-earnings ratio of -2.62, a price-to-earnings-growth ratio of 1.27 and a beta of 1.33. The business has a fifty day moving average of $19.85 and a 200-day moving average of $19.61. The company has a quick ratio of 1.76, a current ratio of 2.04 and a debt-to-equity ratio of 0.44.

Envista (NYSE:NVST) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. As a group, analysts predict that Envista will post 1 earnings per share for the current fiscal year.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.